References
Barekatain A, Razavi M. Antiarrhythmic therapy in atrial fibrillation: indications, guidelines, and safety. Tex Heart Inst J. 2012;39:532–4.
Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI Jr, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016;129:468–75.
Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149:1378–80. e1.
Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373:1886–8.
Anonymous. FDA warns of serious slowing of the heart rate when the antiarrhythmic drug amiodarone us used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. Available from: www.fda.gov. Accessed May 17, 2015.
Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149:1315–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghembaza, M.E.A., Lounici, A. Bradyarrhythmia induced by amiodarone-sofosbuvir co-administration. Indian J Gastroenterol 35, 319–320 (2016). https://doi.org/10.1007/s12664-016-0684-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12664-016-0684-6